EU Clinical Trials Register. www.clinicaltrialsregister.eu. An agency of the European Union



Similar documents
XML Conversion Utility User Awareness

How to search the EU Clinical Trials Register

Regulatory approval routes in the European System for Medicinal Products

Clinical Trial Transparency. What is available?

Questions and answers on post approval change management protocols

EMA esignature capabilities: frequently asked questions relating to practical and technical aspects of the implementation

Adoption by GCP Inspectors Working Group for consultation 14 June End of consultation (deadline for comments) 15 February 2012

Questions and answers on post approval change management protocols

The European regulatory system for medicines and the European Medicines Agency

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions. Title: How to create reports from scientific memory database (SMD)

Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points to consider

Submission of comments on 'Policy 0070 on publication and access to clinical-trial data'

The Clinical Trials Regulation EU No 536/2014: and Phase I trials

EMA Update Clinical Trials

EU Change Control Process for Change Requests in the Entire Area of Electronic Submissions for Human Medicinal Products Version 2.

Standard operating procedure

POST-AUTHORISATION GUIDANCE. Human Medicinal Products

Adoption by CHMP for release for consultation November End of consultation (deadline for comments) 31 March 2011

European Medicines Agency decision

Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies

EU PAS Register Guide

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES

Reflection paper on clinical aspects related to tissue engineered products

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

Submission of comments on 'Policy 0070 on publication and access to clinical-trial data'

The EU portal and database

London, 15 March 2007 Doc. Ref.: EMEA/409282/2006 Direct Line (44-20)

Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)

Clinical Trials Register

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples

End of consultation (deadline for comments) 14 October Adoption by Committee for advanced therapies 15 October 2010

Annex VI Service Level Agreement for Medical Service Provider

Clinical research: where are we with the new (Paediatric) RC trial Regulation

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

Chemicals and Life Sciences Industry Practice. Insurance and compensation in the event of injury in Phase I clinical trials in the United Kingdom

Implementation strategy for ISO IDMP in EU

Date : Date of start of procedure: Authorisation/ positive opinion :

Questions and answers relating to Restricted tender procedure EMA/2012/19/IS Provision of Security Consultancy Services

Clinical trials submitted in marketing-authorisation applications to the European Medicines Agency

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

Clinical trials regulation

BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports

Compilation of Community Procedures on Inspections and Exchange of Information

Early Phase Clinical Trials: Public Access to the EU Database Repository

Questions & answers on signal management

QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

EMA pharmacovigilance system manual

Clinical trials in developing countries submitted to EMEA for regulatory purposes

Regulation of clinical trials with medicinal products: Where are we now?

Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems

II. AREA OF INVOLVEMENT OF PATIENTS AND CONSUMERS IN EMEA ACTIVITIES

Questions and answers relating to Open Procedure EMA ED Online Strategy and Interface Design

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

Guideline on stability testing for applications for variations to a marketing authorisation

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector

Reflection paper on non-spontaneous adverse event reports (peer-reviewed literature, internet and social media)

PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Questions and answers relating to Open Tender EMA/2012/21/IS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Standard operating procedure

SETTING UP INTERNATIONAL CLINICAL TRIALS IN EUROPE: THE EORTC EXPERIENCE

The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010

All the steps detailed in this WIN are carried out by the assistant in the Sampling and Testing Team in the MQC Section.

EU Clinical Trials Register

Standard operating procedure

Work plan for GMP/GDP Inspectors Working Group for 2016

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

Technical specifications for open invitation to tender

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

European Medicines Agency decision

The EMA current activities towards ISO IDMP implementation

Strategy and pilot phase for patient registries

extended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual

Workshop on multiple sclerosis

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Standard Operating Procedure. Clinical Trial Authorisation

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions EXPLANATORY NOTES

ICH guideline E2C (R2) Periodic benefit-risk evaluation report (PBRER)

Sheffield Kidney Institute. Planning a Clinical Trial

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

Standard operating procedure

Singapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

How To Understand The Paediatric Regulation

Clinical Trials Facilitation Groups

Legal and governance framework

EUDRAVIGILANCE TELEMATICS IMPLEMENTATION GROUP

Draft agreed by the QWP February Draft adopted by the CHMP for release for consultation March Draft endorsed by the CMD(h) March 2015

Post-authorisation safety studies and the EU PAS Register

Draft agreed by the QWP February Draft adopted by the CHMP for release for consultation March Draft endorsed by the CMD(h) March 2015

Transcription:

EU Clinical Trials Register www.clinicaltrialsregister.eu An agency of the European Union

The EU Clinical Trials Register provides public access to information from the European Union (EU) clinical trial database (EudraCT). It forms part of EudraPharm, the EU database of authorised medicinal products. The EU Clinical Trials Register gives users the possibility to search for information on any paediatric clinical trial, any Phase II-IV adult clinical trial recorded in EudraCT, and any trial listed in a paediatric investigation plan. The paediatric clinical trials include those with investigator sites in the EU and also those which form part of a paediatric investigation plan where the investigator sites are outside the EU. EudraCT includes trials in EEA as well as EU Member States.

EU Clinical Trials Register website www.clinicaltrialsregister.eu What the EU Clinical Trials Register contains The EU Clinical Trials Register website provides access to information on interventional clinical trials on medicines. The information available dates from 1 May 2004, when national medicine regulatory authorities began populating EudraCT, the application that is used by national medicines regulatory authorities to enter clinical trial data. The website, launched on 22 March 2011, enables users to search for information that has been included in the EudraCT database. Users are able to view: description of phase II-IV adult clinical trials where the investigator sites are in EU Member States or the European Economic Area (EEA);

description of paediatric clinical trials with investigator sites in the EU and trials which form part of a paediatric investigation plan (PIP), including those where the investigator sites are outside the EU. The EU Clinical Trials Register website does not: provide information on the results of clinical trials (this will come later); provide information on non-interventional clinical trials of medicines (observational studies on authorised medicines); provide information on clinical trials for surgical procedures, medical devices or psychotherapeutic procedures. Clinical trial description Details in the clinical trial description include: the design of the trial; the sponsor; the investigational medicine (trade name or active substance identification); the therapeutic areas; the status (authorised, ongoing, complete). Data sources Information that appears on the EU Clinical Trials Register website is originally provided by the company or organisation responsible for the clinical trial, and is a component of its application to a national medicine regulatory authority for authorisation to conduct a trial.

The information from the company or organisation is loaded into the EudraCT database by the national medicine regulatory authority. The authority adds to this information the authorisation of the clinical trial and the opinion from the relevant ethics committee. The information on clinical trials that are part of a PIP and are conducted outside of the EU or the EEA is supplied by the company or organisation responsible for the PIP. Advice regarding use of data displayed Publication of information on a clinical trial in the EU Clinical Trials Register does not constitute any form of authorisation of that trial, nor is it an endorsement of the scientific, clinical or ethical aspects of the trial or of the information presented. Patients should not interpret the information as a recommendation to use the medicine or to participate in the trial. Patients should consult their treating physician or the trial investigator to discuss appropriate treatment options.

Further information European Medicines Agency Clinical Trials Register Service Desk 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom E-mail euctr@ema.europa.eu Website www.ema.europa.eu European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.